This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Activity Details
256 | Mon, 8/2/2010, 2:00 PM - 3:50 PM | CC-Exhibit Hall A (West) |
Contributed Oral Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations | ||
Biopharmaceutical Section | ||
Chair(s): Peiyong (Annie) Qu, University of Illinois at Urbana-Champaign | ||
01: | Validation of a Monte-Carlo Markov Model for Schizophrenia — Alice Dragomir, Université de Montréal ; Jean-Francois Angers, Université de Montréal ; Jean-Eric Tarride, McMaster University ; Syvie Perreault, Université de Montréal | |
02: | WITHDRAWN: Functional Mixed-Effects Modeling of Electroencephalographic (EEG) Data — Shubhankar Ray, Merck & Co., Inc. | |
03: | Statistical Evaluation of Nonprofile Analyses for In Vitro Bioequivalence — Jen-pei Liu, National Taiwan University | |
05: | Power and Robustness of Nonparametric Covariate Adjustment Methods for Ordinal Data — Muhtarjan Osman, North Carolina State University ; Wei Tian, Inspire Pharmaceuticals | |
06: | A Multiple Imputation Approach for Estimating Rank Correlation with Left-Censored Data — John M. Williamson, CDC ; Sara B. Crawford, Valparaiso University ; Hung-Mo Lin, Mount Sinai School of Medicine | |
07: | Establishing Sample Size in Clinical Trials Having Multiple Hypotheses — Alan Barry Davis, Pharmanet Development Group, Inc. ; Mary M. Poole, Pharmanet Development Group, Inc. ; Young Kim, Pharmanet Development Group, Inc. | |
08: | Correcting an Incorrect Statistical Practice in Pharmacokinetics and Related Fields — Jingyuan Wang, Millennium Pharmaceuticals, Inc. | |
09: | WITHDRAWN: Statistics in Bioprocess Development — Priya Kulkarni, Genentech ; Dan Coleman, Genentech | |
10: | Longitudinal Methods for Analysis of Tumor Burden Data — Ritwik Sinha, Bristol-Myers Squibb ; Aparna B. Anderson, Bristol-Myers Squibb | |
11: | Statistical Considerations on Validating Microarray Platform in Clinical Development — Guang (Gary) Chen, Merck & Co., Inc. ; Christopher Ramsborg, Merck & Co., Inc. ; Yue Wang, Merck & Co., Inc. ; Miho Kibukawa, Merck & Co., Inc. ; Joel A. Klappenbach, Merck & Co., Inc. | |
12: | Harmonic Regression Analysis of Periodic Time Series Data from Clinical Trials — Michael T. Gaffney , Pfizer Inc. ; Martin O. Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. | |
13: | Adjusted Cumulative Distribution Function and Effect Size Methods for Stratified Two-Sample Comparisons — Kelly H. Zou, Pfizer Inc. ; Martin O. Carlsson, Pfizer Inc. ; Ching-Ray Yu, Pfizer Inc. | |
14: | Characterizing the Mutation Pathway for Integrase Inhibitor — Jing Zhao, Merck Research Laboratories | |
15: | Calculating an Exact p-Value for a Noninferiority Test on Matched Pair Data — Jennifer E. Hamer-Maansson, AstraZeneca | |
16: | Analysis of Overall Survival When Length of Treatment and Treatment Switching Are Time-Dependent Outcomes of Oncology Trials — Jinwei Yuan, ICON Clinical Research | |
17: | WITHDRAWN: Hierarchical Poisson Regression Model with Application to Efficacy Data of ZOSTAVAXTM for Evaluating Vaccine Waning Effect — Shu-Chih Su, Merck & Co., Inc. | |
18: | Definition of a Responder in Clinical Trials for Alcohol Dependence — Yun-Fei Chen, Eli Lilly and Company ; Xiwen Ma, University of Wisconsin-Madison | |
19: | WITHDRAWN: Bayesian Methods in Combination Drug Studies: A Performance Analysis — Peiqi Zhai, Southern Methodist University | |
20: | Semiparametric AUC Model with Placement Values — Lin Zhang, Quintiles ; Jack Tubbs, Baylor University | |
21: | Transfer of Methods Supporting Biologics and Vaccines — Rong Liu, Merck & Co., Inc. ; Timothy Schofield, GlaxoSmithKline ; Jason Liao, Merck Research Laboratories | |
22: | A Simulation Study to Evaluate Dose-Response in Dose-Titration Clinical Trials: A Dynamic Linear Mixed Effect (DLME) Modeling Approach — Xu Steven Xu, Johnson & Johnson ; Min Yuan, Fudan University, China ; Julia Wang, Johnson & Johnson ; Partha Nandy, Johnson & Johnson | |
23: | WITHDRAWN: Comparison of Imputation Methods for the Delayed Start Design in Studies of Alzheimer's Disease — Kathryn Dawson, PPD, Inc. | |
24: | Survival Methods for Modeling the Time to Drop-Out in Pain Studies — Tilda Chuang, Abbott Laboratories ; Wei Liu, Abbott Laboratories ; Sandeep Dutta, Abbott Laboratories | |
25: | In Vitro Drug Combination Analysis in Excel: A Case Study in HIV — Karen Chiswell, GlaxoSmithKline ; Katja Sabine Remlinger, GlaxoSmithKline ; Mark Underwood, GlaxoSmithKline | |
26: | Evaluating Endpoint Determination and Approaches for Handling Missing Data in Pain Trials — Lindsey Lian, PPD, Inc. ; Benjamin Luke Peterson, PPD, Inc. | |
27: | Analysis of Statistical Tests to Compare Cumulative Proportion of Responders for Pain Data in Clinical Trials — Song Wang, PPD, Inc. | |
28: | Comparison of Longitudinal Analyses of Binary Outcome Data: Marginal Models vs. Generalized Linear Mixed Models — Qian Dong, Merck Sharp & Dohme Corp. | |
29: | Recent Development in Exact Inference for Categorical Data — Dar Shong Hwang, B.R.S.I. ; James Lee, Daiichi Sankyo Pharma Development | |
30: | The Use of Contrast-Enhancing Lesions to Predict Imminent Relapse: Validating Cutter's Rule — Charity Johanna Morgan, The University of Alabama at Birmingham ; Ashutosh Ranjan, The University of Alabama at Birmingham ; Gary Cutter, University of Alabama at Birmingham | |
31: | Competing Risks Methods in Safety Analysis of Oncology Clinical Trials — Sofia Paul, Novartis Pharmaceuticals Corporation ; Bingqing Zhou, The University of North Carolina at Chapel Hill ; Samit Hirawat, Novartis Pharma ; Glen Laird, Novartis Pharmaceuticals Corporation | |
32: | Identifying Treatment Responsive Trajectory Classes in a Depression Trial: An Alternative Statistical Approach — Maggie Kuchibhatla, Duke University Medical Center ; Gerda Fillenbaum, DUMC | |
33: | A Bootstrap Approach to Estimating Antibody Levels in Case of Non-Normal Data — Roger Maansson, Merck & Co., Inc. | |
34: | Implementation of EWOC (Escalation With Overdose Controls) Adaptive Dose-Finding Design in a Phase IIA Clinical Trial — Catherine Bresee, Oschin Comprehensive Cancer Institute ; Amir Steinberg, Oschin Comprehensive Cancer Institute ; Jeremy Rudnick, Oschin Comprehensive Cancer Institute ; Andre Rogatko, Oschin Comprehensive Cancer Institute | |
35: | Analyzing Correlated Binary Data: Examples from Aquaculture Studies — Kyunghee Kim Song, FDA/CDRH ; Todd Blessinger, HHS/FDA/CVM | |
36: | Comparison of Power for ANCOVA Models Based on Central Tendency versus Nonparametric Analysis of Cumulative Responders for Clinical Trials with Continuous Response Endpoints — Kevin L. Lawson, PPD, Inc. | |
37: | Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs — Liping Huang, Bayer HealthCare Pharmaceuticals | |
38: | A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials — Lixin Lang, Bristol-Myers Squibb ; Ralph Raymond, Bristol-Myers Squibb | |
39: | A Model for Multilevel Clustered Data with Informative Cluster Size Using Poisson Distribution — Ana-Maria Iosif, University of California, Davis ; Allan Sampson, University of Pittsburgh | |
40: | Using Pilot Study for Clinical Study Planning — Hongbin Gu, The University of North Carolina at Chapel Hill ; Xiaofei Wang, Duke University |
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.